Skip to Content

Posts tagged with "Infectious Diseases"

  • Infectious Diseases

    A Mistake About Making Mistakes

    Most of the people reading this blog have some knowledge of chemistry and/or biology. (Not everyone, though – I get email from readers with no formal training who just stop by to hear what’s going on, and I’m very happy to have them). But if you do know a lot about a subject, any subject… Read More
  • Drug Development

    Idiocy On Drug Research Costs

    Here’s a piece from the Center for Economic and Policy Research that claims to have the whole high-drug-price problem figured out. It’s “incredibly inefficient research”, just so you know. How does the CEPR know, you ask? They do a comparison of the costs of research (as provided by the Center for the Study of Drug Developm… Read More
  • Drug Industry History

    C-Nucleosides Never Went Away

    Here’s a paper in J. Med. Chem. calling for a revival of work in the C-nucleoside area. To some extent, these compounds never went away, but it’s certainly true that there was a period where many more groups were working on them. When I was looking for an undergraduate research project to do during my… Read More
  • Alzheimer's Disease

    A Fungal Origin For Alzheimer’s?

    Here’s a potentially interesting paper that’s recently appeared, saying that numerous brain regions in Alzheimer’s patients appear to show signs of fungal infection, as opposed to control samples. The authors claim detection through antibodies, and to have isolated fungal DNA as well, identifying several species. The authors (from… Read More
  • Infectious Diseases

    Does An Ancient Retrovirus Have Anything to Do with ALS?

    One of the reasons that many people think that organisms can carry around “junk” DNA (that has little or no function) is that up to 8% of our own genomes are remnants of ancient retroviruses. At some points in the distant past, some germ-line cells got infected, had viral DNA spliced into them, and then… Read More
  • Chemical News

    Natural Products Drug Discovery Wins a Nobel

    This year’s Physiology/Medicine Nobel has gone to three discoverers of important drugs for topical diseases: William C. Campbell and Satoshi Ōmura for Avermectin, and Youyou Tu for Artemisinin. I last wrote about artemisinin here, with reference to a scale-up synthesis. And scale-up is a useful topic with that one, because it’s one… Read More
  • Drug Assays

    The Antifungal Literature Has Problems

    Antifungals are one of the areas I’ve never actually done any drug research in. But I’ve always heard that it’s a hard row to hoe, to use an expression from my upbringing on the Mississippi Delta. Fungi have some unusual biochemical pathways, and thus some good potential drug targets, but getting those to work in… Read More
  • Business and Markets

    Martin Shkreli Has One Idea, And It’s a Bad One

    Martin Shkreli may finally have overstepped, and it will be a good thing if he has. Let me back up both those statements. Shkreli, you may recall, was the founder of Retrophin, a company whose business model was to buy up obscure orphan generic drugs (such as Thiola) and immediately raise their price by, say… Read More
  • Drug Assays

    Screening Against Some of the Worst Organisms

    The traditional way to kill off infectious organisms is to treat the patient with some agent that targets a step in the pathogen’s life cycle, but not in human biochemistry. The classic antibiotics all work in this fashion, hitting bacterial proteins that either don’t exist in humans or are sufficiently different to avoid cross-reactivi… Read More
  • Business and Markets

    GlaxoSmithKline’s New Strategy, Defended

    GlaxoSmithKline’s Moncef Slaoui has an interview in the Philadelphia Inquirer, and he’s responding to critics of the company’s strategy (and to rumors about it): Slaoui suggested some reality for pharma cheerleaders: First, most Americans think drug prices are way too high and sooner or later the bottom will fall out from those fi… Read More